ZYMEWORKS INC. Expense Breakdown
No Expense Breakdown for ZYME on this site yet.
- 2026-06-30: Reportable $27.43M.
- 2025-06-30: Reportable $34.45M.
Source checked: the stored Expense Breakdown page for ZYME.
Expenses by product
Research and Development Expense (Excluding Acquired in Process Cost): each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $27.43M |
| 2025-06-30 | $34.45M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |